Table 3.

Patient demographic information for the TOL and SI patient groups used for FACS analyses of TOL cells (n=11 unique patients)

VariableTOL (n=5)aSI (n=6)b
Recipients
 Male patients (%)40.00100.00
 Mean age±SD (yr)24±7.8711±6.86
 Post-transplant time (mo)
  Mean221.854.4
  Median±SD219.1±56.0816.7±64.06
  Minimum/maximum157.7/291.311.9/159.2
 Induction therapyNADaclizumab/antithymocyte globulin
 Maintenance therapy(%)CNI+steroids/MMF, with or without AZA
 Serum creatinine (mg/dl)0.95±0.21.4±0.73
Donors
 LRD donor source (%)8066.70
 HLA mismatchNA0.75±1.5
 Male donor (%)7550
 Donor age (yr)27.5±8.06NA
  • NA, not applicable.

  • a Operational tolerant.

  • b Stable immunosuppression.